Navigation Links
Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
Date:1/5/2011

CRANBURY, N.J., Jan. 5, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that  Chairman and Chief Executive Officer John F. Crowley will be presenting a business update and a review of the Company's expected key milestones for 2011 at the upcoming 29th Annual J.P. Morgan Healthcare Conference.  Mr. Crowley's presentation is scheduled to begin on Tuesday, January 11 at 3:00 p.m. PST.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics web site, http://www.amicustherapeutics.com.  Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.

About Amicus TherapeuticsAmicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of rare diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.  CONTACT:Amicus Therapeutics(609) 662-2000ir@amicustherapeutics.com FOLD-G


'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... prove useful in treating small cell lung cancer - the ... Cancer Research UK Manchester Institute, based at The University of ... up with experts at AstraZeneca, as part of a collaboration ... AZD3965 - on small cell lung cancer cells. , The ... also helps identify which patients are most likely to respond ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2
... privacy in the healthcare sector is an issue of ... address the various issues raised by healthcare consumers regarding ... compliance. Writing in the International Journal of ... Johnson of Dartmouth College, Hanover, New Hampshire, USA, explain ...
... of Southern California (USC) has announced a $24 million charitable ... multi-million dollar gift will support cancer research directed by renowned ... School of Medicine of USC and director of the USC ... Cancer Center. The donation to the Keck ...
... HealthDay Reporter , THURSDAY, July 15 (HealthDay News) -- ... percent watch more than the recommended two hours of television ... rest of the country," said study co-author Dr. John Oh, ... Disease Control and Prevention, working with Oregon Public Health. ...
... Cancer Research Institute (CRI) is conducting a clinical trial that ... Lymphoma, which affects the white blood cells ... or T-cell. About 85% of lymphomas are of B-cell origin, ... chronic, but they do not respond well to chemotherapy. ...
... used to treat cancer may someday help clean up environmental ... powder hidden underneath clothing. The novel radiation mechanism developed ... team of scientists in Japan also could help doctors more ... of treatments on healthy parts of the body. The ...
... DURHAM, N.C. -- A team of Duke University researchers ... the spread of malaria while protecting human and environmental ... mosquito-borne disease occurs will be supported by a $2.2 ... Health. "We,ll be performing experiments in 24 villages ...
Cached Medicine News:Health News:Insecurities plague electronic health care 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 3Health News:Too Many Tots Watching Too Much TV: Study 2Health News:Too Many Tots Watching Too Much TV: Study 3Health News:Duke and African partners to study sustainable malaria control 2
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: